Rinvoq ER 15 MG tablet UU 30S
Ended Awarded
- Contract number
- SPE2DB25FXLK0
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $28,283
Award facts
- Contract value 100% obligated
- $28,282.61 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $28,282.61 delivery order for RINVOQ ER 15 MG tablets (30-count units) on August 6, 2025, with completion targeted for August 7, 2025. This non-set-aside contract was competitively awarded under a firm fixed-price arrangement and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used in the treatment of rheumatoid arthritis and other inflammatory conditions, representing part of the company's broader pharmaceutical supply portfolio for federal military and veteran healthcare systems.
This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime contract vehicle extending through December 2026 that enables the company to supply an extensive range of pharmaceutical products and medical commodities globally. As a major pharmaceutical distributor, AmerisourceBergen Drug Corp supplies critical medications across multiple therapeutic domains to support military healthcare programs, the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. The firm's demonstrated capacity to fulfill federal procurement requirements through open competition across product categories ranging from specialty medications to vaccines and medical devices makes it a key vendor within the DLA's pharmaceutical supply chain.
Quick answers
Who was awarded contract SPE2DB25FXLK0?
SPE2DB25FXLK0 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on August 6, 2025.
How much is contract SPE2DB25FXLK0 worth?
The government has obligated $28,283 on SPE2DB25FXLK0.
Is contract SPE2DB25FXLK0 an order under another contract?
Yes. SPE2DB25FXLK0 is a delivery order under SPE2DB24D2003, an indefinite delivery contract.
Was contract SPE2DB25FXLK0 competed?
The extent of competition for SPE2DB25FXLK0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award